Cancer cells often evade the host immune system, challenging the effectiveness of immunotherapy. In this comprehensive review, Galassi et al. summarize key mechanisms of immune evasion within the “three Cs” framework—camouflage, coercion, and cytoprotection—and discuss promising strategies to target these mechanisms for therapeutic purposes.
MI Cancer Seek has been granted FDA approval as a companion diagnostic for patients with cancer who may benefit from targeted therapy.
Cancer Discovery | 14 | 11 | November 2024
The FDA has granted orphan drug designation to LBL-034 for the treatment of patients with multiple myeloma.
Pegylated liposomal doxorubicin showed promise in a single-arm trial, but randomized trials are needed, according to researchers.
Matthew Cortese, MD, MPH, details 2024/2025 updates to the NCCN guidelines for CLL/SLL and treatments to look forward to in the future.
Shaji Kumar, MD, details key updates/revisions made to the multiple myeloma NCCN guidelines in 2024 and the first version of the 2025 guidelines.
Researchers sought to determine whether liso-cel could be safely administered as an outpatient therapy in relapsed/refractory LBCL.
November 15 – 16, 2024, Philadelphia, Pennsylvania. The conference brings together experts and thought leaders from around the world to discuss the mechanism of toxicities…
Alessandra Ferrajoli, MD, discusses the importance of supportive care in the management of patients with chronic lymphocytic leukemia with comorbidities.
Bowman et al. develop orthogonal DNA recombinase tools to sequentially and reversibly control somatic mutations in leukemic evolution. These approaches identify how mutation timing and order…
